PDS Biotech to Present at the LD Micro Main Event XV
PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the LD Micro Main Event XV on October 26, 2022, at 4:30 PM PDT in Beverly Hills, California.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the LD Micro Main Event XV on October 26, 2022, at 4:30 PM PDT in Beverly Hills, California. The company focuses on targeted immunotherapies for cancer and infectious diseases through its Versamune® and Infectimune™ technology platforms. The lead candidate, PDS0101, shows promise in reducing tumors in HPV-positive cancers. Interested parties can access the presentation via a livestream.
Details
News Market Reaction – PDSB
The recorded move for PDSB in the trading session of this news was -2.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that its management will present at the LD Micro Main Event XV conference being held at the Luxe Sunset Boulevard Hotel in Beverly Hills, California, on October 25-27, 2022.
LD Micro Main Event XV
Presentation Date: Wednesday, October 26, 2022
Time: 4:30 PM PDT
Virtual viewers: Livestream
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-positive cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.
Investor Contacts:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital
Media Contacts:
Dave Schemelia
Tiberend Strategic Advisors Inc.
Phone: +1 (609) 468-9325
Email: dschemelia@tiberend.com
Bill Borden
Tiberend Strategic Advisors Inc.
Phone: +1 (732) 910-1620
Email: bborden@tiberend.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.